ALKBH5 and ovarian serous cystadenocarcinoma: In addition, ALKBH5 has been reported to form an ALKBH5–HOXA10 cycle with its upstream factor HOXA10, which enhances cisplatin (CDDP) resistance in ovarian serous cystadenocarcinoma (OV) by mediating JAK2 m6A demethylation.109